Biologics: Targets & Therapy

Dovepress
open access to scientific and medical research

Open Access Full Text Article

REVIEW

The old and new therapeutic approaches to the treatment of giardiasis: Where are we?

Biologics: Targets and Therapy downloaded from https://www.dovepress.com/
For personal use only.

Haendel GNO Busatti[1]
Joseph FG Santos[2]
Maria A Gomes[1]

[1]Departmento de Parasitologia, ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Brasil; [2]Hospital Santa Casa de Misericórdia de Belo Horizonte, Minas Gerais, Brasil

Correspondence: Maria Aparecida Gomes
Departamento de Parasitologia, ICB-UFMG, Av. Antonio Carlos, 6627, 31270-901, Belo Horizonte, Minas Gerais, Brasil
Tel +55 31 3409 2846
Fax +55 31 3409 2970
Email magomes@icb.ufmg.br

Abstract: *Giardia lamblia* is the causative agent of giardiasis, one of the most common parasitic infections of the human intestinal tract. This disease most frequently affects children causing abdominal pain, nausea, vomiting, acute or chronic diarrhea, and malabsorption syndrome. In undernourished children, giardiasis is a determining factor in retarded physical and mental development. Antigiardial chemotherapy focuses on the trophozoite stage. Metronidazole and other nitroimidazoles have been used for decades as the therapy of choice against giardiasis. In recent years many other drugs have been proposed for the treatment of giardiasis. Therefore, several synthetic and natural substances have been tested in search of new giardicidal compounds. This study is a review of drugs used in *in vitro* and *in vivo* tests, and also drugs tested in clinical trials (nonrandomized and randomized).

Keywords: *Giardia lamblia*; treatment; new drugs

Introduction

Giardia lamblia (syn. *Giardia intestinalis*, *Giardia duodenalis*) is a flagellate protozoan which may be found infecting the human small intestine, causing a disease called giardiasis. The symptomatology of human giardiasis is extremely variable, many individuals have the asymptomatic form while some have abdominal pain, nausea, acute or chronic diarrhea – which may last several months, malabsorption and weight loss.[1–3] The clinical impact seems to be stronger in the first three years of life and in undernourished or immunodeficient individuals.[4] *G. lamblia* has often been pointed out as the cause of growth disorders among children,[3] also with the presence and frequency of diarrhea, for as long as the infection lasts, and the opportunity of reinfection, all constituting essential factors behind children's physical and mental debilitation.[5]

G. lamblia is found in mammals, including human beings, cats, dogs, beavers, and cattle. Giardiasis is transmitted by the ingestion of cysts present in food and water; water dissemination being easier due to cysts resistance to chlorination.[6,7] Cysts are highly infectious to men. Human volunteers have been experimentally infected with as few as 10 cysts.[8] These cysts may remain viable in the environment for up to three months under favorable conditions of temperature and humidity. Three aspects are important in the epidemiological context of the disease: the cysts' resistance to the environment, the amount of cysts eliminated by the patients, and the zoonotic aspect of the disease.[9]

Epidemics, in developed countries, have been attributed to an inappropriate water treatment, to its contamination with human or animal feces, particularly in surface

submit your manuscript | www.dovepress.com
Dovepress

© 2009 Busatti et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

water collections and lakes.[9] Direct transmission from person to person is another infection mechanism, particularly important in collective institutions, such as daycare centers and orphanages, among members of the same family, and between male homosexual partners.[10] In these populations, giardiasis reaches epidemic levels. *G. lamblia* has a cosmopolitan distribution with an estimated number of 2.8×10^8 cases of infections per year and is thus the most common intestinal parasite in humans in developed countries.[11] In Asia, Africa, and Latin America, about 200 million people have symptomatic giardiasis with some 500,000 new cases reported each year.[12] In those countries this disease should be observed carefully, for it contributes substantially to generating mentally and physically impaired adults.

Thompson and colleagues[13] reviewed publications by several authors who reported genetic variations among *Giardia* samples isolated from human beings. Such differences are believed to significantly influence giardiasis epidemiology and control, particularly for host susceptibility, virulence, drug sensitivity, antigenicity, and *in vivo* and *in vitro* development.[5] Although some advances have been observed in isolating and characterizing *Giardia* samples, there are few studies regarding this parasite`s chemotherapy.[14] Resistance to different drugs used in the treatment of this disease has been reported and the number of cases is likely to increase.[15–17]

A variety of chemotherapeutic agents such as 5-nitroimidazole compounds, quinacrine, furazolidone, paromomycin, benzimidazole compounds, nitazoxanide have been used in the therapy for giardiasis. Nevertheless, therapeutic regimens and therapy reviews are little explored. Most drugs used have considerable adverse effects and, most of the time, they are contraindicated.[18–20] Furthermore, *Giardia* seems to have a great ability to resist these agents.[17,19,21,22]

In this context, the study of new chemotherapeutic agents plays a fundamental role – along with the reviews of the actually used drugs – in the rationale for treatment of giardiasis on the basis of more consistent data.

Many compounds have shown giardicidal activity in *in vivo* models or in animal models. In the present review, we have systematically addressed the main *in vitro* and *in vivo* studies and prospective trials in human population concerning the treatment of giardiasis.

Methodology

This is a review of giardiasis treatment in which we analyze the quality of the studies published in the Medline, PubMed, and EMBASE databases from 1966 to September, 2008.

Concentrating only on studies published in English, for each class of study (see below), we looked up the following key words in various combinations: giardia, giardiasis, treatment, therapeutic, therapy, drug, medication, phytotherapy, and chemotherapy. In those studies performed in humans, we did not have an age limit and searched for children and adult patients.

The studies were divided into four classes. Group I: *in vitro* studies; group II: *in vivo* studies; group III: clinical trials, nonrandomized, controlled or not; group IV: randomized control trials (RCT), blinded or not.

Inclusion criteria

We included the following studies: *In vitro* studies consisting of studies that tested the sensitivity and efficacy of the drugs against *Giardia*; *In vivo* studies consisting of studies that tested the efficacy of drugs against *Giardia* in experimental animals; Nonrandomized clinical trials consisting of studies that tested the efficacy of drugs against *Giardia* in humans; Randomized controlled clinical trials (RCT) consisting of studies designed to compare the efficacy between different drugs, between drugs and placebo, or to compare different schemes of the same drug in humans. These studies were necessarily randomized and controlled, but not necessarily blinded.

This review was made using two independent reviewers following the same inclusion criteria for searching the articles simultaneously. After they were finished, the reviews were analyzed. Those articles showing up in two reviews were automatically included in the final analysis. The remaining nonconsensual studies were analyzed by a third reviewer for a final decision as to include or exclude an article after the discussion between the first two reviewers was exhausted.

Statistical analysis

Data are presented as mean ± standard deviation (confidence interval [CI]), absolute numbers, or percentages. Comparisons between rates of cure of drugs were made using the chi-squared or the Student *t*-test methods. Only variables with $p < 0.05$ were considered significant.

Main results

In the initial search, 116 *in vitro* studies, 48 *in vivo* studies, 87 nonrandomized clinical trials, and 47 RCT were found. After selection for the inclusion criteria, 39 *in vitro* studies, nine *in vivo* studies, 23 nonrandomized clinical trials, and 34 RCTs remained (Tables 1–4).

Table 1 In vitro studies

Year	Drugs/Substances	Activity	Reference
1975	2,2-biimidazole	Yes	23
1983	Human milk	Yes	24
1984	Metronidazole	Yes	61
	Tinidazole	Yes (+ effective)	
	Furazolidone	Yes	
	Quinacrin	Yes (– effective)	
1985	Bithionol	Yes	25
	Dichlorophene	Yes	
	Hexachlorophene	Yes	
1985	Clomipramine	Yes	26
1986	Furazolidone	Yes	27
	Nitroimidazole	Yes	
1990	Azitromicin/Furazolidone	Yes	28
	Doxiciclin/Mefloquin	Yes	
	Doxiciclin/Tinidazole	Yes	
	Mefloquin/Tinidazole	Yes	
1991	Metronidazole	Yes	29
	Ornidazole	Yes	
1991	Azitromicin	Yes	30
1994	Serum immune specific	Yes	31
1994	Agglutinin of wheat germ	Yes	32
1994	Derivatives of allicin (diallyl trisulfide)	Yes	60
1995	Phytotherapics popular in Africa	Yes (+ effective)	33
	Methanolic extracts cathartics	Yes (– effective)	
	Methanolic extracts noncathartics		
1995	Albendazole	Yes (– effective)	34
	Metronidazole	Yes (+ effective)	
1999	Derivatives of flavonoid *Helianthenum glomeratum*	Yes	59
2001	Pyrantel pamoate	Yes	35
2001	Powder of Yucca schidigera	Yes	36
2001	Ciprofloxacin	Yes	37
2002	Nitazoxanide	Yes (+ effective)	38
	Albendazole	Yes (+ effective)	
	Metronidazole	Yes (– effective)	
2002	Mucin	Yes	39
2002	Derivatives of isoflavone	Yes	40
2003	Derivative etylphenylcarbamate	Yes (– effective)	41
	Albendazole	Yes (+ effective)	
2004	Gangliosides	Yes	42
2004	Derivate phenyl-carbamate	Yes (- effective)	43
	Albendazole	Yes (+ effective)	
2004	S-substituted 4,6-dibromo-mercaptobenzimidazole	Yes	58
	S-substituted 4,6-dichloro-2-mercaptobenzimidazole	Yes	
2005	Dodecanoic acid	Yes	44
	Metronidazole	Yes	
2005	Arsenic sodium	No	45
2005	Derivatives of *Artemisia ludoviciana*	Yes	57
2005	Derivatives of flavonoid glycosides	Yes	56
2006	Derivatives benzimidazoles	Yes (+ effective)	46
	Albendazole	Yes (++ effective)	
	Metronidazole	Yes (– effective)	

(*Continued*)

Table 1 *(Continued)*

Year	Drugs/Substances	Activity	Reference
2006	Nitrotiazol (Nitazoxanide)	Yes	47
	Metronidazole	Yes	
2006	Venom *Crotalus durissus terrificus*	Yes	48
	Venom *Bothrops jararaca*	Yes	
2006	Propolis	Yes	49
2006	Curcumin	Yes	50
2006	Metronidazole	Yes	55
	Furazolidone	Yes (+ effective)	
2006	*Dorstenia contrajerva*	Yes	54
	Senna villosa	Yes	
	Ruta chalepensis	Yes	
2007	Metronidazole	Yes (– effective)	51
	Analogous MTZ-Ms	Yes	
	Analogous MTZ-I	Yes	
	Analogous MTZ-Br	Yes	
	Analogous MTZ-N_3	Yes	
	Analogous MTZ-NH_3Cl	Yes	
2007	Extracts of blueberry	Yes	52
2007	Tiliroside	Yes (+ effective)	53
	Kaempferol-glucopyranoside	Yes	
	Astragalin	Yes	
	Quercitrin	Yes	
	Isoquercitrin	No	

In the 39 *in vitro* studies selected, 55 drugs were tested, 53 (96.4%) showed activity against giardia. Eighteen studies (46.2%) did not have comparative design with other drugs. Twenty-one studies (53.8%) compared activity between drugs: 11 (52.4%) compared activity between two drugs, and 10 (47.6%) compared activity between three or more drugs.

The most frequently tested drugs in *in vitro* studies were: metronidazole (nine studies, 16.4%), albendazole (five studies, 9.1%), furazolidone (four studies, 7.3%), azitromicyn, nitazoxanide, phenyl-carbamate derivatives, tinidazole, and kaempferol (two studies each, 3.6%). The other drugs had one study each (Table 5).

In the nine *in vivo* studies selected in which nine drugs were tested, eight (88.9%) showed activity against *Giardia*. One of them compared the efficacy between two drugs (11.1%), and the remaining study tested just one drug (Table 2).

Out of the 23 nonrandomized clinical trials, six studies (26.1%) had design to compare efficacy between drugs, three (13%) compared different schemes of the same drug, and three (13%) compared efficacy between one drug and placebo (nonrandomized). Eleven studies evaluated the effect of one drug without comparing either dosages or efficacy between drugs (see Table 3).

Twelve drugs have been tested in the 23 nonrandomized clinical trials, with an average sample size of 83.3 ± 53.3 patients per study (confidence interval [CI] = 57.2 to 109.4). The mean general rate of cure (RC) per drug was 85.5% ± 16.7 (CI = 80.0 to 91.0). The most frequently tested drugs were: metronidazole (nine studies, 39.1%), tinidazole (seven studies, 30.4%), ornidazole, and quinacrine (three studies each, 13%), secnidazole, furazolidone, and berberine (two studies each, 8.7%) (Table 7). In evaluating drug effectiveness, the following mean rates of cure were found: secnidazole (RC = 96% ± 2.8), ornidazole (RC = 93.6% ± 1.2), tinidazole (RC = 89.1% ± 8.8),

Table 2 *In vivo* studies

Year	Drugs/Substances	Activity	Reference
1991	Albendazole	Yes	62
1993	New oxadiazoles	Yes (+ effective)	63
	Metronidazole	Yes (– effective)	
1996	Ivermectin	Yes	64
1998	Disulfiram (Antabuse)	Yes	65
2000	Oxifendazole	Yes	66
2001	Ivermectin	Yes	67
2002	Inmunoglobulin (IgA)	Yes	68
2003	Vaccine against Giardia	No	69
2007	Antioxidant (Antox)	No	70

Table 3 Nonrandomized clinical trials

Year	Drugs/Substances	Activity	Reference
1972	Berberine	Yes	71
1975	Berberine	Yes	72
1977	Metronidazole Tinidazole Nimorazol Furazolidone	Yes Yes Yes Yes (– effective)	73
1978	Tiberal 1 g BID – G1 Tiberal 50 mg/Kg/single dose – G2	Yes Yes SE > group G2	74
1978	Metronidazole in four dosage schedules	Yes (+ effective in extended systems)	75
1978	Metronidazole Tinidazole	 Yes (– effective) Yes (+ effective) SE > with metronidazole	76
1978	Tinidazole Placebo	 Yes (+ effective)	77
1978	Tinidazole single dose highest Tinidazole seven days dose lower	 Yes (+ effective) Yes (– effective)	78
1979	Metronidazole Quinacrine	 Yes (+ effective) Yes (– effective)	79
1979	Ornidazole	 Yes	80
1980	Metronidazole seven days Meronidazole single dose Quinacrine Tinidazole Ornidazole	 Yes (– effective) Yes (– effective) Yes (+ effective) Yes (+ effective) Yes (+ effective) SE > with ornidazole	81
1981	Furazolidone Quinacrine	 Yes (+ effective) Yes (– effective) SE > with quinacrine	82
1987	Metronidazole Tinidazole Ornidazole	 Yes Yes Yes Similar	83
1987	Tinidazole	efficiencies	84
1995	Metronidazole	Yes	85
1997	Metronidazole + diloxanide	Yes	86
1997	Pippali Rasayana Placebo	Yes Yes	87
1998	Albendazole		88
1999	Secnidazole	Yes	89
2000	Secnidazole	Yes	90
2008	Metronidazole	Yes Yes	91

Abbreviations: BID, twice a day; SE, side effects.

Table 4 Randomized controlled clinical trials

Year	Drugs	Activity	Reference
1970	Mepacrine Metronidazole Furazolidone	–	92
1977	Tinidazole Metronidazole	Yes (+ effective and < SE) Yes (– effective and > SE)	93
1978	Tinidazole Metronidazole	–	94
1978	Tinidazole Placebo	Yes (+ effective)	95
1981	Tinidazole Metronidazole	Yes – Similar efficacy	96
1985	Tinidazole Metronidazole	Yes – Similar efficacy with appropriate doses	97
1989	Furazolidone Placebo	Yes	98
1989	Metronidazole Furazolidone	Yes Yes	99
1989	Menbedazole	No	100
1990	Metronidazole Menbendazole	Yes Yes	101
1991	Metronidazole Ornidazole	Yes – Similar efficacy	102
1992	Metronidazole Mebendazole	Yes Yes	103
1994	Metronidazole Albendazole	Effectiveness of cure similar SE > with metronidazole	104
1995	Metronidazole Albendazole	Yes Yes	105
1995	Bacitracin zinc Bacitracin Neomycin Neomycin + Bacitracin zinc	Yes Yes Yes Yes	106
1995	Metronidazole single dose Metronidazole for five days Albendazole for five days	Yes Yes Yes	107
1995	Metronidazole Ornidazole Mebendazole	Yes (effective) Yes (+ effective) Yes (– effective)	108
1999	Albendazole Tinidazole	Yes (+ effective) Yes (– effective)	109
2001	Metronidazole Mebendazole	Yes Yes	110
2001	Nitazoxanide Placebo	Yes (+ effective)	111
2001	Metronidazole Nitazoxanide	Yes – Similar efficacy	112
2001	Metronidazole + wheat germ Metronidazole + Placebo	Yes (+ effective) Yes (– effective)	113
2002	Albendazole Albendazole + Praziquantel Tinidazole	Yes (+ effective) Yes (– effective) Yes (+ effective) Albendazole and Tinidazole with similar effectiveness	114

(*Continued*)

Table 4 (*Continued*)

Year	Drugs	Activity	Reference
2002	Metronidazole Ornidazole single dose Ornidazole five days	Yes (– effective) Yes (+ effective) Yes (+ effective)	115
2003	Mebendazole Secnidazole	Yes Yes	116
2003	Albendazole Tinidazole Cloroquine	Yes (– effective) Yes (+ effective) Yes (+ effective) Tinidazole and Cloroquine with similar effectiveness and greater than Albendazole	117
2004	Metronidazole Albendazole	Yes Yes	118
2004	Metronidazole Albendazole	Yes (– effective) Yes (+ effective)	119
2006	Metronidazole + saccharomyces boulardii Metronidazole +placebo	Yes (+ effective) Yes (– effective)	120
2006	Mebendazole Quinacrine	Yes Yes	121
2006	Mebendazole Tinidazole	Yes (– effective) Yes (+ effective)	122
2006	Metronidazole Albendazole	Yes (– effective) Yes (+ effective)	123
2007	Vitamin A Zinc Vitamin + zinc Placebo	Yes Yes Yes (+ effective) No	124
2008	Tinidazole Nitazoxanide	Yes (+ effective) Yes (– effective)	125

Abbreviation: SE, side effects.

quinacrine (RC = 85% ± 21.6), furazolidone (RC = 82% ± 14), and metronidazole (RC = 76.6% ± 20.6) (Table 8). The metronidazole was the most studied and tested drug for the giardiasis treatment. This drug had greater efficacy in larger doses and in more prolonged regimes (5 to 10 days), and achieved a cure rate of 87% to 100% in these schemes (Table 9).

Out of the 34 RCTs selected for analysis, 23 studies (67.6%) had design to compare efficacy between drugs, five (14.7%) compared different schemes of the same drug, and five (14.7%) compared efficacy between one drug and placebo (randomized). One study tested a drug without comparing it with any other drug or placebo. Eight studies (23.5%) were double-blind studies, five (62.5%) compared one drug with placebo, while three (37.5%) compared the efficacy between drugs.

Eighteen drugs were tested on the 34 RCTs. The average sample size was 98.9 ± 38.0 patients per study (CI = 83.7 to 114.1). The mean general rate of cure per drug was 83.0% ± 16.1 (CI = 78.4 to 87.6). Interestingly, the mean rate of cure of the placebo was 25%.

There was no significant difference either in the sample size/patient relationship or in the rate of cure observed between nonrandomized and RCTs studies (83.3 × 98.9 patients/study and 85.5% × 83.0%; $p > 0.05$).

The most frequently tested drugs in RCTs were: metronidazole (21 studies, 61.8%), tinidazole (10 studies, 29.4%), albendazole (nine studies, 26.5%), mebendazole (eight studies, 23.5%), ornidazole, furazolidone, and nitazoxanide (three studies each, 8.8%) (Table 10).

Among drugs showing greater effectiveness, the following mean rates of cure were found: ornidazole (RC = 97.6% ± 2.5), tinidazole (RC = 91.1% ± 6.3), metronidazole (RC = 81.5% ± 18.6), nitazoxanide (RC = 79.7% ± 1.8), and albendazole (RC = 73.4% ± 19.8) (Table 11). According to the nonrandomized clinical trials, metronidazole was the drug most frequently studied and

Table 5 *In vitro* studies: drugs more frequently tested

	Drugs/Substances tested	Number of studies	Observation
1	2,2-biimidazole	1	–
2	Human milk	1	–
3	Bithionol	1	–
4	Dichlorophene	1	–
5	Hexachlorophene	1	–
6	Clomipramine	1	–
7	Furazolidone	4	*
8	Nitroimidazole	1	–
9	Azitromicin	2	*
10	Doxiciclin	1	–
11	Mefloquin	1	–
12	Tinidazole	2	*
13	Metronidazole	9	*
14	Ornidazole	1	–
15	Serum immune specific	1	–
16	Agglutinin of wheat germ	1	–
17	Methanolic extracts cathartics	1	#
18	Methanolic extracts noncathartics	1	#
19	Albendazole	5	*
20	Pyrantel pamoate	1	–
21	Powder of *Yucca schidigera*	1	–
22	Ciprofloxacin	1	–
23	Nitazoxanide (Nitrotiazol)	2	*
24	Mucin	1	–
25	Derivatives of isoflavone	1	–
26	Derivative etylphenylcarbamate	2	*
27	Gangliosides	1	–
28	Dodecanoic acid	1	–
29	Arsenic sodium	1	–
30	Derivatives benzimidazoles	1	–
31	Venom *Crotalus durissus terrificus*	1	–
32	Venom *Bothrops jararaca*	1	–
33	Propolis	1	–
34	Curcumin	1	–
35	Analogous MTZ-Ms	1	–
36	Analogous MTZ-I	1	–
37	Analogous MTZ-Br	1	–
38	Analogous MTZ-N_3	1	–
39	Analogous MTZ-NH_3Cl	1	–
40	Extracts of blueberry	1	–
41	Tiliroside	1	–
42	Kaempferol-glucopyranoside	2	*
43	Astragalin	1	–
44	Quercitrin	1	–
45	Isoquercitrin	1	–
46	Dorstenia contrajerva	1	–
47	Senna villosa	1	–
48	Ruta chalepensis	1	–

(*Continued*)

Table 5 (*Continued*)

	Drugs/Substances tested	Number of studies	Observation
49	Derivatives of flavonoid glycosides	1	–
50	Derivatives of *Artemisia ludoviciana*	1	–
51	S-substituted 4,6-dibromo mercaptobenzimidazole	1	–
52	S-substituted 4,6-dichloro-2-mercaptobenzimidazole	1	–
53	Derivatives of flavonoid Helianthenum glomeratum	1	–
54	Derivatives of allicin (diallyl trisulfide)	1	–
55	Quinacrin	1	–

Notes: #phytotherapies are popular in Africa; *Drugs more frequently tested.

tested on the RCTs. Likewise, this drug had greater efficacy with larger doses and with more prolonged regimes (5 to 10 days), reaching cure rates of 89% to 97% with these schemes (Table 12).

On the RCTs, tinidazole and ornidazole were the drugs which showed good efficacy using a single-dose scheme. Albendazole shown great variability in efficacy, not only in a single dose (RC = 50% to 97%), but also in prolonged regimes (RC = 62% to 90%).

The side effects were poorly described in the majority of studies in the nonrandomized control trials, and they ranged from none to 59%, although they were mild and transient. As in nonrandomized clinical trials, the prevalence of side effects were poorly described in the majority of RCTs studies, ranging from few or absent to 70%, and were also mild and transient.

Discussion

In 1957, the Rhone-Poulenc laboratories synthesized 1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole (metronidazole) by manipulating the chemical structure of 2-nitroimidazole[126] and this proved to be a highly effective agent against *Trichomonas vaginalis* infections.[127] In 1962, Darbon and colleagues[128] reported that this could also be used in treatments against giardiasis. Thus, since it was discovered, metronidazole and other 5-nitroimidazoles – such as secnidazole, ornidazole, and tinidazole – are used by physicians to treat *G. lamblia* infections in addition to infections by other microorganisms. Nowadays, metronidazole is the most used drug to treat giardiasis worldwide; including in the USA.[129] However, the number of new drugs is increasing.

Doing this review, we found out that there were a high number of studies regarding the giardiasis treatment, even with the methodology used in the present study. However, the quality of them was very poor, mainly regarding their primary goal, their design, and sample size; in addition to a great heterogeneity detected between studies.

In all categories of studies, 298 were initially included (*in vitro*, *in vivo*, nonrandomized clinical trials, and RCTs), which, after selection, comprised 105 studies – representing 35.2% – that constituted the sample for the analysis. It is important to point out that we used relatively liberal criteria to select the articles, and the search was done only in the most important databases, comprising journals with more restricted and rigorous publication criteria.

One hundred and sixteen references to *in vitro* studies were found, which comprised 39 (33.6%) studies that constituted the data bank for analysis. Based on this, 50 drugs were evaluated, 48 (96%) of which showing activity against Giardia. Most of these studies had design to compare drugs among themselves (53 %): 52.4% to compare two drugs, and 47.6% to compare three or more drugs.

Many of the studies with two or more drugs did not necessarily compare the efficacy between drugs, but just analyzed and described the activity of the drugs without comparing their efficacy.

Although the number of known drugs tested was larger, we found out that the most widely tested drugs were metronidazole, albendazole, and furazolidone, and that the new drugs were larger in number, each with few studies (Table 5). In this context, several *in vitro* studies have been carried out in order to search for new substances with antigiardial activity. This way, many methods have been described aiming at determining the antigiardial activity of drugs *in vitro*.[4,19,64,130–133] However, some of these are laborious and require long and hard work; furthermore, they are very difficult to reproduce for they lack standardization.

In the initial search for new drugs with antigiardial activity, 48 *in vivo* studies were found but only nine (18.8%) constituted the data bank for analysis, according to the inclusion criteria. Ten drugs were tested in these studies, and eight (80%) were active against *Giardia*. The majority of studies did not compare drugs, but just tested the activity of one drug against *Giardia* (Tables 2 and 6).

Table 6 *In vivo* studies: drugs more frequently tested

	Drugs tested	Number of studies	Observation
1	Albendazole	1	–
2	News oxadiazoles	1	–
3	Metronidazole	1	–
4	Ivermectin	2	*
5	Disulfiram (Antabuse)	1	–
6	Oxifendazole	1	–
7	Inmunoglobulin (IgA)	1	–
8	Vaccine against Giardia	1	–
9	Antioxidant (Antox)	1	–

Note: *Drugs more frequently tested.

Table 8 Mean rate of cure of drugs more tested in nonrandomized clinical trials

	Drugs tested	Number of studies	Mean rate of cure % ± SD (CI)
1	Metronidazole	9	76.6 ± 20.6 (64.9–88.3)
2	Tinidazole	7	89.1 ± 8.8 (83–92.5)
3	Ornidazole	3	93.6 ± 1.2 (92.2–95)
4	Quinacrin	3	85 ± 21.6 (63.8–100)
5	Secnidazole	2	96 ± 2.8 (92.0–99.9)
6	Furazolidone	2	82 ± 14.0 (62.5–100)

Note: *Drugs more frequently tested.
Abbreviations: CI, confidence interval; SD, standard deviation.

Again, the various models used and the absence of standardized design, besides the heterogeneity of these studies, make the comparative analysis difficult. In this context, several *in vivo* experimental models have been proposed. They are often beavers, young and adult rats,[134–137] rabbits,[138] dogs,[139] cats,[140] mice,[141,142] and gerbils.[143,144] However, the best results have only been obtained in gerbil experimental models. Gerbil (*Meriones unguiculatus*) is considered by several researchers the most appropriate experimental model for giardiasis due to its size, facility to handle, high susceptibility to infections, and large shedding of cysts in their feces.[143–148] Thus, we consider that the absence of standardized methods between studies limited the comparative analysis.

When we analyze the studies in human beings (nonrandomized trials and randomized control trials), we find great heterogeneity among them, besides the poor quality of their methodology.

Table 7 Drugs more frequently tested in nonrandomized clinical trials

	Drugs tested	Number of studies	Observation
1	Berberine	2	*
2	Metronidazole	9	*
3	Tinidazole	7	*
4	Nimorazole	1	–
5	Furazolidone	2	*
6	Tiberal	1	–
7	Quinacrin	3	*
8	Ornidazole	3	*
9	Diloxanide	1	–
10	Pippali Rasayana	1	–
11	Albendazole	1	–
12	Secnidazole	2	*

Note: *Drugs more frequently tested.

No references selected were similar in design, dosages, duration of treatment, and results, which led to a great difficulty in grouping them according to the tested drug (required time or percentage of fecal cure, independent of duration of treatment). These findings agree with those by Zaat and colleagues.[149]

In the nonrandomized clinical trials, slightly more than a quarter of studies compared the efficacy between drugs, whereas 47.8% tested drugs without comparing them to a placebo or to another drug, just appraising their efficacy in treated patients versus untreated patients. Only 13% compared a drug to a placebo.

On the RCTs, we find that two thirds of the studies (67.6%) compared the efficacy between drugs; however, only 14.7% compared drugs to a placebo. Here, just one study did not include a comparison between drugs. About half the nonrandomized clinical trials tested different dosages of drugs (assessment of therapeutic schemes), whereas the RCTs were comparative studies of efficacy between drugs, with few studies using a placebo for comparing the efficacy of drugs (14.7%).

Regarding the number of drugs tested, we built an extensive list of them: 55 drugs in 39 *in vitro* studies, nine

Table 9 More effective doses of drugs tested in nonrandomized clinical trials

Drugs	Unit	Recommended doses
Metronidazole	mg/Kg/day	15–25 TID – 5 to 10 days
	mg	200–500 TID – 5 to 10 days
Tinidazole	mg	1–2 MID – One day
Ornidazole	mg	2 MID – One day
Quinacrine	mg	100 TID – 5 days
Secnidazole	mg/Kg	30 MID – One day

Abbreviations: TID, three times a day; MID, once a day.

Table 10 Drugs more frequently tested in randomized control clinical trials

	Drugs tested	Number of studies	Observation
1	Mepacrine	1	–
2	Metronidazole	21	*
3	Furazolidone	3	*
4	Tinidazole	10	*
5	Mebendazole	8	*
6	Ornidazole	3	*
7	Albendazole	9	*
8	Bacitracin zinc	1	–
9	Neomycin	1	–
10	Nitazoxanide	3	*
11	Wheat germ	1	–
12	Praziquantel	1	–
13	Cloroquine	1	–
14	Secnidazole	1	–
15	Saccharomyces boulardii	1	–
16	Quinacrin	1	–
17	Vitamin A	1	–
18	Zinc	2	–

Note: *Drugs more frequently tested.

drugs in nine *in vivo* studies, 12 drugs in 23 nonrandomized trials, and 18 drugs in 50 RCTs (Tables 1–4).

Regarding the sample size, in human studies, we found a comparatively small sample size in both nonrandomized and RCTs studies. We found a higher sample size in the RCTs as compared to the nonrandomized studies, though not statistically significant (98.9×83.3 patients/study; $p < 0.05$).

These findings show a great number of studies in which the external validation, and, consequently, the generalizability of the results is jeopardized. Numerous confounding factors make the analysis of these studies difficult, mainly due to problems in controlling some variables in the population studied.

The most frequently tested drugs in the present review are listed in Tables 5, 6, 7, and 10. We find that the most used drugs in human studies were all tested in *in vitro* studies, but not all drugs tested in *in vivo* studies were tested in human studies, although the number of drugs in the *in vivo* studies was as low as 10 drugs. Metronidazole was the most frequently tested drug. They were tested in 16.4% of *in vitro* studies, in 11.1% of *in vivo* studies, in 39.1% of nonrandomized studies, and in 61.8% of RCTs. Thus, this drug was the main drug in the available arsenal for giardiasis treatment, constituting a

Table 11 Mean rate of cure of drugs in randomized control clinical trials

	Drugs tested	Number of studies	Mean rate of cure % ± SD (CI)
1	Metronidazole	21	81.5 ± 18.6 (71.0–92.0)
2	Tinidazole	10	91.1 ± 6.3 (87.2–95.0)
3	Albendazole	9	73.4 ± 19.8 (58.7–88.1)
4	Mebendazole	8	65.6 ± 17.3 (50.4–80.8)
5	Ornidazole	3	97.6 ± 2.5 (95.4–99.8)
6	Nitazoxanide	3	79.7 ± 1.8 (77.2–82.2)

Note: *Drugs more frequently tested.
Abbreviations: CI, confidence interval; SD, standard deviation.

reference in relation to other drugs. This finding corroborates other reviews.[149,150]

When only the nonrandomized and RCTs studies were analyzed, the two most tested drugs were metronidazole and tinidazole. However, mebendazole and albendazole were among the most tested in RCTs, and they were barely tested in nonrandomized studies.

We also noticed that the "new drugs" for giardiasis treatment were barely tested in all categories of studies reviewed in this work, either in *in vitro* studies or in RCTs. This demonstrates the difficulty in adequately testing one drug for giardiasis in order to have alternatives in case of resistance to one of the therapeutic schemes.

In spite of the large amount of drugs used in antigiardial therapy, some resistance has been reported regarding different therapeutic regimens, and this resistance has been mentioned by clinicians.[18,20,151] This characteristic makes *Giardia* a fearful microorganism, mainly among undernourished people, in whom the malabsorption syndrome is more common. In this scenario, developing and screening new antigiardial drugs seems to be a priority.

Table 12 More effective doses of drugs tested in randomized clinical trials

Drugs	Unit	Recommended doses
Metronidazole	mg/Kg/day	15–50 TID – 5 to 10 days
	mg	500–750 TID – 5 to 10 days
Tinidazole	mg	2 MID – One dose
	mg/Kg/day	50 MID – One dose
Albendazole	mg	400 MID – One day
	mg	400 MID – 5 days
	mg/Kg/day	10 MID – 5 days
Mebendazole	mg	200 TID – 5 days
Ornidazole	mg/Kg/day	20–40 MID – 1 to 5 days
Nitazoxanide	mg	500 MID – 3 days

Abbreviations: TID, three times a day; MID, once a day.

In order to analyze the optimal dosages for the most tested drugs, we evaluated the mean rate of cure for all (Tables 8 and 11). We found out that the most tested drugs and those with more efficacy in studies with human beings were tinidazole and metronidazole; though ornidazole had a great efficacy not only in nonrandomized but also in RCTs. However, ornidazole was tested in only six studies in the present review (three nonrandomized and three RCTs).

The optimal dosages found in this review for most drugs were those that achieved the best rate of cure for each drug separately. Tables 8, 9, 11, and 12 show the most widely used drugs and their mean rate of cure, along with the optimal dosages for each. Comparing the mean rate of cure between the most tested drugs, we detected a similar efficacy among them, none being better than the others, except for mebendazole in the RCTs.

The analyses of the side effects have been poorly appraised and documented in most studies. Apparently, they have been similar in all studies, and no drug was reported to be unsafe, causing only mild to moderate and transient side effects.

However, regarding the new drugs, only those tested in human beings had their side effects described, but we have few data about it at the moment.

In summary, in this review we found many studies on the giardiasis treatment; however, most of them presented various problems concerning the sample size, methodology, design, among others.

Moreover, the number of drugs tested was large, with a relative higher number of new drugs listed, mainly in the *in vitro* studies, and a lower number in the studies with humans. However, these new drugs were barely tested as compared to the old drugs, mainly in humans, increasing the need for new studies to provide standardization for the evaluation of antigiardial drugs. This can provide more accuracy and quickness for approval, as well as an adequate use not only for the new drugs but also the old ones.

Conclusion

In conclusion, this review raises some problems regarding the evidence for using old and new antigiardial drugs, in relation to the quality of previous and future studies. Yet, one must point out that the drugs in use nowadays are the most widely tested and that they are safe, although we must rethink and further study the problem of their increasing resistance.

Acknowledgments

We are grateful for the financial support of FAPEMIG. The authors report no conflicts of interest in this work.

References

1. Meyer EA, Radulescu S. *Giardia* and Giardiasis. *Adv Parasitol*. 1979;17:1–47.
2. Ungar BLP, Yolken RH, Nash TE, et al. Enzyme-linked immunosorbent assay for the detection of *Giardia lamblia* in fecal specimens. *J Infect Dis*. 1984;149(1):90–97.
3. Goldin AJ, Werner APT, Aguilera X, et al. Efficient diagnosis of giardiasis among nursery and primary school children in Santiago, Chile by capture ELISA for the detection of fecal *Giardia* antigens. *Am J Trop Med Hyg*. 1990;42(6):538–545.
4. Farthing MJG. Host parasite interactions in human *Giardia*sis. *Quart J Med*. 1989;70(263):191–204.
5. Thompson RCA, Reynoldson JA, Mendis AHW. *Giardia* and Giardiasis. *Adv Parasitol*. 1993;32:71–160.
6. Fayer R. Cryptosporidium: a water-borne zoonotic parasite. *Vet Parasitol*. 2004;126(1–2):37–56.
7. Thompson RC. The zoonotic significance and molecular epidemiology of *Giardia* and giardiasis. *Vet Parasitol*. 2004;126(1–2):15–35.
8. Rendtorff RC. The experimental transmission of human intestinal protozoan parasites II. *Giardia lamblia* cysts given in capsules. *Am J Hyg*. 1954;59(2):209–220.
9. Hunter PR, Thompson RC. The zoonotic transmission of *Giardia* and Cryptosporidium. *Int J Parasitol*. 2005;35(11–12):1181–1190.
10. Ungar BLP, Yolken RH, Nash TE, et al. Enzyme-linked immunosorbent assay for the detection of *Giardia lamblia* in fecal specimens. *J Infect Dis*. 1984;149(1):90–97.
11. Lane S, Lloyd D. Current trends in research into the waterborne parasite *Giardia*. *Crit Rev Microbiol*. 2002;28(2):123–147.
12. World Health Organization. *The World Health Report 1996. Fighting Disease Fostering Development*. Geneva, Switzerland: World Health Organization; 1996.
13. Thompson RCA, Lymbery AJ, Meloni BP. Genetic variation in *Giardia* Kunstler, 1882: taxonomic and epidemiological significance. *Protozool Abstracts*. 1990;14:1–28.
14. Wright JM, Dunn LA, Upcroft P, et al. Efficay of antigiardial drugs. *Expert Opin Drug Saf*. 2003;2:529–541.
15. Johnson PJ. Metronidazole and drug resistance. *Parasitol Today*. 1993;9(5):183–186.
16. Upcroft JA, Dunn LA, Wright JM, et al. 5-Nitroimidazole drugs effective against metronidazole-resistant *Trichomonas vaginalis* and *Giardia duodenalis*. *Antimicrob Agents Chemother*. 2006;50(1):344–347.
17. Long KZ, Rosado JL, Montoya Y, et al. Effect of vitamin A and zinc supplementation on gastrointestinal parasitic infections among Mexican children. *Pediatrics*. 2007;120(4):846–855.
18. Ellis JE, Wingfield JM, Cole D, et al. Oxygen affinities of metronidazole-resistant and -sensitive stocks of *Giardia intestinalis*. *Int J Parasitol*. 1993;23(1):35–39.
19. Upcroft JA, Campbell RW, Benakli K, et al. Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and resistant *Giardia*, *Trichomonas*, and *Entamoeba* spp. *Antimicrob Agents Chemother*. 1999;43(1):73–76.
20. Petri W. Therapy of intestinal protozoa. *Trends Parasitol*. 2003;19(11):523–526.
21. Boreham PFL, Phillips RE, Shepherd RW. Altered uptake of metronidazole *in vitro* by stocks of *Giardia intestinalis* with different drug sensitivities. *Trans R Soc Trop Med Hyg*. 1988;82(1):104–106.
22. Upcroft JA, Upcroft P, Boreham PFL. Drug resistance in *Giardia intestinalis*. *Int J Parasitol*. 1990;20(4):489–496.
23. Melloni P, Metelli R, Bassini DF, et al. Snythesis and antiprotozoal activity of nitro derivatives of 2, 2'-biimidazole. *Arzneimittelforschung*. 1975;25(1):9–14.
24. Gillin FD, Reiner DS, Wang CS. Human milk kills parasitic intestinal protozoa. *Science*. 1983;221(4617):1290–1292.
25. Takeuchi T, Kobayashi S, Tanabe M, et al. *In vitro* inhibition of *Giardia lamblia* and *Trichomonas vaginalis* growth by bithionol, dichlorophene, and hexachlorophene. *Antimicrob Agents Chemother*. 1985;27(1):65–70.

26. Weinbach EC, Costa JL, Wieder SC. Antidepressant drugs suppress growth of the human pathogenic protozoan *Giardia lamblia*. *Res Commun Chem Pathol Pharmacol*. 1985;47(1):145–148.
27. McIntyre P, Boreham PF, Phillips RE, et al. Chemotherapy in giardiasis: clinical responses and *in vitro* drug sensitivity of human isolates in axenic culture. *J Pediatr*. 1986;108(6):1005–1010.
28. Crouch AA, Seow WK, Whitman LM, et al. Sensitivity *in vitro* of *Giardia intestinalis* to dyadic combinations of azithromycin, doxycycline, mefloquine, tinidazole and furazolidone. *Trans R Soc Trop Med Hyg*. 1990;84(2):246–248.
29. Majewska AC, Kasprzak W, De Jonckheere JF, et al. Heterogeneity in the sensitivity of stocks and clones of *Giardia* to metronidazole and ornidazole. *Trans R Soc Trop Med Hyg*. 1991;85(1):67–69.
30. Boreham PFL, Upcroft JA. The activity of azithromycin against stocks of *Giardia intestinalis in vitro* and *in vivo*. *Trans R Soc Trop Med Hyg*. 1991;85(5):620–621.
31. Belosevic M, Faubert GM, Dharampaul S. Antimicrobial action of antibodies against *Giardia muris* trophozoites. *Clin Exp Immunol*. 1994;95(3):485–489.
32. Ortega-Barria E, Ward HD, Keusch GT, et al. Growth inhibition of the intestinal parasite *Giardia lamblia* by a dietary lectin is associated with arrest of the cell cycle. *J Clin Invest*. 1994;94(6):2283–2288.
33. Johns T, Faubert GM, Kokwaro JO, et al. Anti-giardial activity of gastrointestinal remedies of the Luo of east Africa. *J Ethnopharmacol*. 1995;46(1):17–23.
34. Farbey MD, Reynoldson JA, Thompson RC. *In vitro* drug susceptibility of 29 isolates of *Giardia intestinalis* from humans as assessed by anadhesion assay. *Int J Parasitol*. 1995;25(5):593–599.
35. Campanati L, Gadelha AP, Monteiro-Leal LH. Electron and video-light microscopy analysis of the *in vitro* effects of pyrantel pamoate on *Giardia lamblia*. *Exp Parasitol*. 2001;97(1):9–14.
36. McAllister TA, Annett CB, Cockwill CL, et al. Studies on the use of *Yucca schidigera* to control giardiasis. *Vet Parasitol*. 2001;97(2):85–99.
37. Sousa MC, Poiares-da-Silva J. The cytotoxic effects of ciprofloxacin in *Giardia lamblia* trophozoites. *Toxicol In Vitro*. 2001;15(4–5):297–301.
38. Cedillo-Rivera R, Chávez B, González-Robles A, et al. *In vitro* effect of nitazoxanide against *Entamoeba histolytica, Giardia intestinalis* and *Trichomonas vaginalis* trophozoites. *J Eukaryot Microbiol*. 2002;49(3):201–208.
39. Roskens H, Erlandsen SL. Inhibition of *in vitro* attachment of *Giardia* trophozoites by mucin. *J Parasitol*. 2002;88(5):869–873.
40. Mineno T, Stanford KM, Walker LA, et al. Solution-phase parallel synthesis of an isoflavone library for the discovery of novel antigiardial agents. *Comb Chem High Throughput Screen*. 2002;5(6):481–487.
41. Jiménez-Cardoso E, Flores-Luna A, Angeles E, et al. *In vitro* antigiardial activity of IRE-6A and IRE-7B, two ethyl-phenylcarbamate derivatives. *Rev Invest Clin*. 2003;55(4):444–447.
42. Suh M, Belosevic M, Clandinin MT. Dietary lipids containing gangliosides reduce *Giardia muris* infection *in vivo* and survival of *Giardia lamblia* trophozoites *in vitro*. *Parasitology*. 2004;128(Pt 6):595–602.
43. Jiménez-Cardoso E, Flores-Luna A, Pérez-Urizar J. *In vitro* activity of two phenyl-carbamate derivatives, singly and in combination with albendazole against albendazole-resistant *Giardia intestinalis*. *Acta Trop*. 2004;92(3):237–244.
44. Rayan P, Stenzel D, McDonnell PA. The effects of saturated fatty acids on *Giardia duodenalis* trophozoites *in vitro*. *Parasitol Res*. 2005;97(3):191–200.
45. Escudero-Lourdes C, Martínez FD, Medina de la Garza CE, et al. Effect of oral chronic intoxication with sodium arsenite on murine giardiasis. *Proc West Pharmacol Soc*. 2005;48:92–99.
46. Navarrete-Vázquez G, Rojano-Vilchis Mde M, Yépez-Mulia L, et al. Synthesis and antiprotozoal activity of some 2-(trifluoromethyl)-1H-benzimidazole bioisosteres. *Eur J Med Chem*. 2006;41(1):135–141.
47. Müller J, Rühle G, Müller N, et al. *In vitro* effects of thiazolides on *Giardia lamblia* WB clone C6 cultured axenically and in coculture with Caco2 cells. *Antimicrob Agents Chemother*. 2006;50(1):162–170.
48. Shinohara L, de Freitas SF, da Silva RJ, et al. *In vitro* effects of *Crotalus durissus terrificus* and *Bothrops jararaca* venoms on *Giardia duodenalis* trophozoites. *Parasitol Res*. 2006;98(4):339–344.
49. Freitas SF, Shinohara L, Sforcin JM, et al. *In vitro* effects of propolis on *Giardia duodenalis* trophozoites. *Phytomedicine*. 2006;13(3):170–175.
50. Pérez-Arriaga L, Mendoza-Magaña ML, Cortés-Zárate R, et al. Cytotoxic effect of curcumin on *Giardia lamblia* trophozoites. *Acta Trop*. 2006;98(2):152–161.
51. Busatti HGNO, Vieira AED, Viana JC, et al. Effect of metronidazole analogues on *Giardia lamblia* cultures. *Parasitol Res*. 2007;102(1):145–149.
52. Anthony JP, Fyfe L, Stewart D, McDougall GJ, Smith HV. The effect of blueberry extracts on *Giardia duodenalis* viability and spontaneous excystation of *Cryptosporidium parvum* oocysts, *in vitro*. *Methods*. 2007;42(4):339–348.
53. Calzada F, Alanís AD. Additional antiprotozoal flavonol glycosides of the aerial parts of Helianthemum glomeratum. *Phytother Res*. 2007;21(1):78–80.
54. Calzada F, Yépez-Mulia L, Aguilar A. *In vitro* susceptibility of *Entamoeba histolytica* and *Giardia lamblia* to plants used in Mexican traditional medicine for the treatment of gastrointestinal disorders. *J Ethnopharmacol*. 2006;108(3):367–370.
55. Hausen MA, Freitas JC Jr, Monteiro-Leal LH. The effects of metronidazole and furazolidone during Giardia differentiation into cysts. *Exp Parasitol*. 2006;113(3):135–141.
56. Calzada F. Additional antiprotozoal constituents from Cuphea pinetorum, a plant used in Mayan traditional medicine to treat diarrhoea. *Phytother Res*. 2005;19(8):725–727.
57. Said Fernández S, Ramos Guerra MC, Mata Cárdenas BD, et al. *In vitro* antiprotozoal activity of the leaves of *Artemisia ludoviciana*. *Fitoterapia*. 2005;76(5):466–468.
58. Andrzejewska M, Yepez-Mulia L, Tapia A, et al. Synthesis, and antiprotozoal and antibacterial activities of S-substituted 4,6-dibromo- and 4,6-dichloro-2-mercaptobenzimidazoles. *Eur J Pharm Sci*. 2004;21(2–3):323–329.
59. Meckes M, Calzada F, Tapia-Contreras A, et al. Antiprotozoal properties of *Helianthemum glomeratum*. *Phytother Res*. 1999;13(2):102–105.
60. Lun ZR, Burri C, Menzinger M, et al. Antiparasitic activity of diallyl trisulfide (Dasuansu) on human and animal pathogenic protozoa (*Trypanosoma* sp., *Entamoeba histolytica* and *Giardia lamblia*) *in vitro*. *Ann Soc Belg Med Trop*. 1994;74(1):51–59.
61. Boreham PFL, Phillips RE, Shepherd RW. The sensitivity of *Giardia intestinalis* to drugs *in vitro*. *J Antimicrob Chemother*. 1984;14(5):449–461.
62. Reynoldson JA, Thompson RC, Meloni BP. *In vivo* efficacy of albendazole against *Giardia duodenalis* in mice. *Parasitol Res*. 1991;77(4):325–328.
63. Bhopale KK, Pradhan KS, Phaltankar PG, et al. Activity of a new oxadiazole compound, against experimental infections with *Entamoeba histolytica* and *Giardia lamblia* in animal models. *Ann Trop Med Parasitol*. 1993;87(2):169–178.
64. Wahl SM, Gilman RH, O'Hare J, et al. A new miniculture technique for determining *in vitro* antimicrobial agent sensitivity of axenically cultivated strains of *Giardia lamblia*. In: Hammond BR, Wallis PM, editors. *Advances in Giardia Research*. Calgary, Canada: University of Calgary Press; 1988. p. 21–24.
65. Nash T, Rice WG. Efficacies of zinc-finger-active drugs against *Giardia lamblia*. *Antimicrob Agents Chemother*. 1998;42(6):1488–1492.
66. Villeneuve V, Beugnet F, Bourdoiseau G. Efficacy of oxfendazole for the treatment of giardiosis in dogs. Experiments in dog breeding kennels. *Parasite*. 2000;7(3):221–226.
67. Hassan SI, Nessim NG, Mahmoud SS, et al. Effect of a broad spectrum antiparasitic drug "ivermectin" in acute and chronic experimental giardiasis using different dose regimens. *J Egypt Soc Parasitol*. 2001;31(2):419–428.
68. Langford TD, Housley MP, Boes M, et al. Central importance of immunoglobulin A in host defense against *Giardia* spp. *Infect Immun*. 2002;70(1):11–18.

69. Stein JE, Radecki SV, Lappin MR. Efficacy of *Giardia* vaccination in the treatment of giardiasis in cats. *J Am Vet Med Assoc*. 2003;222(11):1548–1551.
70. El-Taweel HA, El-Zawawy LA, Said DE, et al. Influence of the antioxidant drug (Antox) on experimental giardiasis and microsporidiosis. *J Egypt Soc Parasitol*. 2007;37(1):189–204.
71. Choudhry VP, Sabir M, Bhide VN. Berberine in giardiasis. *Indian Pediatr*. 1972;9(3):143–146.
72. Gupte S. Use of berberine in treatment of giardiasis. *Am J Dis Child*. 1975;129(7):866.
73. Levi GC, Avila CA, Neto VA. Efficacy of various drugs for treatment of giardiasis. A comparative study. *Am J Trop Med Hyg*. 1977;26(3):564–565.
74. Iyngkaran N, Lee IL, Robinson MJ. Single dose treatment with Tiberal of *Giardia lamblia* infection in children. *Scand J Infect Dis*. 1978;10(3):243–246.
75. Jokipii L, Jokipii AM. Comparison of four dosage schedules in the treatment of giardiasis with metronidazole. *Infection*. 1978;6(2):92–94.
76. Gazder AJ, Banerjee M. Single dose therapy of giardiasis with tinidazole and metronidazole. *Drugs*. 1978;15 suppl 1:30–32.
77. Farahmandian I, Sheiban F, Sanati A. Evaluation of the effect of a single dose of tinidazole (Fasigyn) in giardiasis. *J Trop Med Hyg*. 1978;81(7):139–140.
78. Jokipii AM, Jokipii L. Comparative evaluation of two dosages of tinidazole in the treatment of giardiasis. *Am J Trop Med Hyg*. 1978;27(4):758–761.
79. Kavousi S. Giardiasis in infancy and childhood: a prospective study of 160 cases with comparison of quinacrine (Atabrine) and metronidazole (Flagyl). *Am J Trop Med Hyg*. 1979;28(1):19–23.
80. Werkman HP, Meuwissen JH. Single-dose treatment of giardiasis with ornidazole in children. *Lancet*. 1979;2(8156–8157):1373.
81. Sabchareon A, Chongsuphajaisiddhi T, Attanath P. Treatment of giardiasis in children with quinacrine, metronidazole, tinidazole and ornidazole. *Southeast Asian J Trop Med Public Health*. 1980;11(2):280–284.
82. Craft JC, Murphy T, Nelson JD. Furazolidone and quinacrine. Comparative study of therapy for giardiasis in children. *Am J Dis Child*. 1981;135(2):164–166.
83. Bassily S, Farid Z, el-Masry NA, et al. Treatment of intestinal *E. histolytica* and *G. lamblia* with metronidazole, tinidazole and ornidazole: a comparative study. *J Trop Med Hyg*. 1987;90(1):9–12.
84. Cervetto JL, Ramonet M, Nahmod LH, et al. Giardiasis. Functional, immunological and histological study of the small bowel. Therapeutic trial with a single dose of tinidazole. *Arq Gastroenterol*. 1987;24(2):102–112.
85. Nikolić A, Durković-Daković O, Petrović Z, et al. Effects of age-targeted treatment of intestinal parasite infections in Serbia. *J Chemother*. 1995;7(1):55–57.
86. Qureshi H, Ali A, Baqai R, et al. Efficacy of a combined diloxanide furoate-metronidazole preparation in the treatment of amoebiasis and giardiasis. *J Int Med Res*. 1997;25(3):167–170.
87. Agarwal AK, Tripathi DM, Sahai R, et al. Management of giardiasis by a herbal drug 'Pippali Rasayana': a clinical study. *J Ethnopharmacol*. 1997;56(3):233–236.
88. Penggabean M, Norhayati, Oothuman P, et al. Efficacy of albendazole in the treatment of *Trichuris trichuria* and *Giardia intestinalis* infection in rural Malay communities. *Med J Malaysia*. 1998;53(4):408–412.
89. Qureshi H, Baqai R, Mehdi I, et al. Secnidazole response in amoebiasis and giardiasis. *East Mediterr Health J*. 1999;5(2):389–390.
90. Di Prisco MC, Jiménez JC, Rodríguez N, et al. Clinical trial with secnidazole in a single dose in Venezuelan children infected by *Giardia intestinalis*. *Invest Clin*. 2000;41(3):179–188.
91. Monajemzadeh SM, Monajemzadeh M. Comparison of iron and hematological indices in *Giardia lamblia* infection before and after treatment in 102 children in Ahwaz, Iran. *Med Sci Monit*. 2008;14(1):19–23.
92. Bassily S, Farid Z, Mikhail JW, et al. The treatment of *Giardia lamblia* infection with mepacrine, metronidazole and furazolidone. *J Trop Med Hyg*. 1970;73(1):15–18.
93. Gazder AJ, Banerjee M. Single-dose treatment of giardiasis in children: a comparison of tinidazole and metronidazole. *Curr Med Res Opin*. 1977;5(2):164–168.
94. Krishnamurthy KA, Saradhambal V. Single dose therapy of giardiasis: a comparative study of tinidazole and metronidazole in pediatric patients. *Indian Pediatr*. 1978;15(1):51–56.
95. Masry NA, Farid Z, Miner WF. Treatment of giardiasis with tinidazole. *Am J Trop Med Hyg*. 1978;27(1 Pt 1):201–202.
96. Kyrönseppä H, Pettersson T. Treatment of giardiasis: relative efficacy of metronidazole as compared with tinidazole. *Scand J Infect Dis*. 1981;13(4):311–312.
97. Speelman P. Single-dose tinidazole for the treatment of giardiasis. *Antimicrob Agents Chemother*. 1985;27(2):227–229.
98. Okhuysen PC, DuPont HL, Flores Lopez JF, et al. A comparative study of furazolidone and placebo in addition to oral rehydration in the treatment of acute infantile diarrhea. *Scand J Gastroenterol Suppl*. 1989;169:39–46.
99. Quiros-Buelna E. Furazolidone and metronidazole for treatment of giardiasis in children. *Scand J Gastroenterol Suppl*. 1989;169:65–69.
100. Gascon J, Moreno A, Valls ME, et al. Failure of mebendazole treatment in *Giardia lamblia* infection. *Trans R Soc Trop Med Hyg*. 1989;83(5):647.
101. Gascon J, Abós R, Valls ME, et al. Mebendazole and metronidazole in giardial infections. *Trans R Soc Trop Med Hyg.* 1990;84(5):694.
102. Oren B, Schgurensky E, Ephros M, et al. Single-dose ornidazole versus seven-day metronidazole therapy of giardiasis in Kibbutzim children in Israel. *Eur J Clin Microbiol Infect Dis*. 1991;10(11):963–965.
103. al-Waili NS, Hasan NU. Mebendazole in giardial infection: a comparative study with metronidazole. *J Infect Dis.* 1992;165(6):1170–1171.
104. Dutta AK, Phadke MA, Bagade AC, et al. A randomised multicentre study to compare the safety and efficacy of albendazole and metronidazole in the treatment of giardiasis in children. *Indian J Pediatr*. 1994;61(6):689–693.
105. Misra PK, Kumar A, Agarwal V, et al. A comparative clinical trial of albendazole versus metronidazole in giardiasis. *Indian Pediatr.* 1995;32(3):291–294.
106. Andrews BJ, Panitescu D, Jipa GH, et al. Chemotherapy for giardiasis: randomized clinical trial of bacitracin, bacitracin zinc, and a combination of bacitracin zinc with neomycin. *Am J Trop Med Hyg.* 1995;52(4):318–321.
107. Misra PK, Kumar A, Agarwal V, et al. A comparative clinical trial of albendazole versus metronidazole in children with giardiasis. *Indian Pediatr.* 1995;32(7):779–782.
108. Bulut BU, Gülnar SB, Aysev D. Alternative treatment protocols in giardiasis: a pilot study. *Scand J Infect Dis.* 1996;28(5):493–495.
109. Pengsaa K, Sirivichayakul C, Pojjaroen-anant C, et al. Albendazole treatment for *Giardia intestinalis* infections in school children. *Southeast Asian J Trop Med Public Health*. 1999;30(1):78–83.
110. Sadjjadi SM, Alborzi AW, Mostovfi H. Comparative clinical trial of mebendazole and metronidazole in giardiasis of children. *J Trop Pediatr.* 2001;47(3):176–178.
111. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by *Giardia intestinalis* and *Entamoeba histolytica* or *E. dispar*: a randomized, double-blind, placebo-controlled study of nitazoxanide. *J Infect Dis*. 2001;184(3):381–384.
112. Ortiz JJ, Ayoub A, Gargala G, et al. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. *Aliment Pharmacol Ther*. 2001;15(9):1409–1415.
113. Grant J, Mahanty S, Khadir A. Wheat germ supplement reduces cyst and trophozoite passage in people with giardiasis. *Am J Trop Med Hyg*. 2001;65(6):705–710.
114. Pengsaa K, Limkittikul K, Pojjaroen-anant C. Single-dose therapy for giardiasis in school-age children. *Southeast Asian J Trop Med Public Health*. 2002;33(4):711–717.
115. Ozbilgin A, Ertan P, Yereli K, et al. Giardiasis treatment in Turkish children with a single dose of ornidazole. *Scand J Infect Dis*. 2002;34(12):918–920.

116. Escobedo AA, Cañete R, Gonzalez ME, et al. A randomized trial comparing mebendazole and secnidazole for the treatment of giardiasis. *Ann Trop Med Parasitol*. 2003;97(5):499–504.
117. Escobedo AA, Núñez FA, Moreira I, et al. Comparison of chloroquine, albendazole and tinidazole in the treatment of children with giardiasis. *Ann Trop Med Parasitol*. 2003;97(4):367–371.
118. Karabay O, Tamer A, Gunduz H et al. Albendazole versus metronidazole treatment of adult giardiasis: An open randomized clinical study. *World J Gastroenterol*. 2004;10(8):1215–1217.
119. Yereli K, Balcioğlu IC, Ertan P, et al. Albendazole as an alternative therapeutic agent for childhood giardiasis in Turkey. *Clin Microbiol Infect.* 2004;10(6):527–529.
120. Besirbellioglu BA, Ulcay A, Can M, et al. *Saccharomyces boulardii* and infection due to *Giardia lamblia*. *Scand J Infect Dis*. 2006;38 (6–7):479–481.
121. Canete R, Escobedo AA, Gonzalez ME, et al. Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children. *World J Gastroenterol.* 2006;12(39):6366–6370.
122. Cañete R, Escobedo AA, González ME, et al. A randomized, controlled, open-label trial of a single day of mebendazole versus a single dose of tinidazole in the treatment of giardiasis in children. *Curr Med Res Opin*. 2006;22(11):2131–2136.
123. Alizadeh A, Ranjbar M, Kashani KM, et al. Albendazole versus metronidazole in the treatment of patients with giardiasis in the Islamic Republic of Iran. *East Mediterr Health J*. 2006;12(5):548–554.
124. Lindquist HD. Induction of albendazole resistance in *Giardia lamblia*. *Microb Drug Resist*. 1996;2(4):433–434.
125. El-Taweel HA, El-Zawawy LA, Said DE, et al. Influence of the antioxidant drug (Antox) on experimental giardiasis and microsporidiosis. *J Egypt Soc Parasitol*. 2007;37(1):189–204.
126. Maeda K, Osato T, Umeza H. A new antibiotic: Azomycin. *J Antibiot*. 1953;6A:182.
127. Cosar C, Julou L. Activitc de 1`(hydroxy-2-ethyl)-1-methyl-2-nitro-5-imidazole (8,823 RP) vis-à-vis des infections experimentales *Trichomonas vaginalis. Ann Inst Pasteur*. 1959;96:238–241.
128. Darbon A, Portal A, Girier L, et al. Treatment of giardiasis (lambliasis) with metronidazole. *Presse Med*. 1962;70:15–16.
129. Gardner TB, Hill DR. Treatment of Giardiasis. *Clin Microbiol Rev*. 2001;14(1):114–128.
130. Boreham PFL, Phillips RE, Shepherd RW. The sensitivity of *Giardia intestinalis* to drugs *in vitro*. *J Antimicrob Chemother*. 1984;14(5): 449–461.
131. Wright CW, Melwani SI, Phillipson JD, et al. Determination of antigiardial activity *in vitro* by mean of soluble formazan production. *Trans R Soc Trop Med Hyg*. 1992;86(5):517–519.
132. Kang EW, Clinch K, Furneaux RH, et al. A novel and simple colorimetric method for screening *Giardia intetinalis* and anti-giardial activity *in vitro*. *Parasitol*. 1998;117(Pt 3):229–234.
133. Busatti HGNO, Gomes MA. A simple colourimetric method to determine anti-giardial activity of drugs. *Parasitol Res*. 2007;101(3):819–821.
134. Sehgal AK, Grewal MS, Chakravarti RN, et al. Experimental giardiasis in albino rats. *Indian J Med Res*. 1976;64(7):1015–1018.
135. Vinayak VK, Sharma GL, Naik SR. Experimental *Giardia lamblia* infection in Swiss mice – a preliminary report. *Indian J Med Res*. 1979;70:195–198.
136. Craft JC, Nelson JD. Diagnosis of giardiasis by counterimmunoelectrophoresis of feces. *J Infect Dis.* 1982;145(4):499–504.
137. Hill DR, Guerrant RL, Pearson RD, et al. *Giardia lamblia* infection of suckling mice. *J Infect Dis.* 1983;147(2):217–221.
138. Schleinitz P, Justus P, Stenzel P, et al. A successful introduction of culture adapted *Giardia intestinalis* in rabbit model: ultrastructural features. *Gastroenterology*. 1983;84:1301.
139. Hewlett EL, Andrews JS, Ruffier Jr, et al. Experimental infection of mongrel dogs with *Giardia lamblia* cysts and cultures trophozoites. *J Infect Dis.* 1982;145(1):89–93.
140. Kirkpatrick CE, Grenn GA. Susceptibility of domestic cats to infections with *Giardia lamblia* cysts and trophozoites from human sources. *J Clin Microbiol*. 1985;21(5):678–680.
141. Barbosa E, Calzada F, Campos R. Antigiardial activity of methanolic extracts from *Helianthemum glomeratum* Lag and *Rubus coriifolius* Focke in suckling mice CD-1. *J Ethnopharmacol.* 2006;108(3):395–397.
142. Barbosa E, Calzada F, Campos R. *In vivo* antigiardial activity of three flavonoids isolated of some medicinal plants used in Mexican traditional medicine for the treatment of diarrhea. *J Ethnopharmacol*. 2007;109(3):552–554.
143. Belosevic M, Faubert GM, Maclean JD, et al. *Giardia lamblia* infections in Mongolian Gerbils: an animal model. *J Infect Dis*. 1983; 147(2):222–226.
144. Araújo NS, Mundim MJS, Gomes MA, et al. *Giardia duodenalis*: Pathological alterations in gerbils, *Meriones unguiculatus*, infected with different dosages of trophozoites. *Exp Parasitol*. 2008;118(4):449–457.
145. Faubert GM, Belosevic M, Walker TS, et al. Comparative studies on the pattern of infection with *Giardia* spp. In Mongolian gerbils. *J Parasitol*. 1983;69(5):802–805.
146. Vivesvara GS, Smith PD, Healy GR, et al. An immunofluorescence test to detect serum anibodies to *Giardia lamblia*. *Ann Intern Med*. 1988;93(6):802–805.
147. Buret A, Galli DG, Olson ME. Growth, activities of enzymes in the small intestines and ultrastructure of microvillous border in gerbils infected with *Giardia duodenalis*. *Parasitol Res*. 1991;77(2):109–114.
148. Mohamed SR, Faubert GM. Dissacharidase deficiencies in Mongolian gerbils (*Meriones unguiculatus*) protected against *Giardia lamblia*. *Parasitol Res*. 1995;81(7):582–590.
149. Zaat JO, Mank TH, Assendelft WJ. WITHDRAWN: Drugs for treating giardiasis. *Cochrane Database Syst Rev*. 2007;2:CD000217.
150. Escobedo AA, Cimerman S. Giardiasis: a pharmacotherapy review. *Expert Opin Pharmacother*. 2007;8(12):1885–1902.
151. Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. *Clin Microbiol Rev*. 2001;14(1):150–164.

Biologics: Targets & Therapy

Dovepress

Publish your work in this journal

Biologics: Targets & Therapy is an international, peer-reviewed journal focusing on the patho-physiological rationale for and clinical application of Biologic agents in the management of autoimmune diseases, cancers or other pathologies where a molecular target can be identified. This journal is indexed on PubMed Central, CAS, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/biologics-targets--therapy-journal